TCL Archive Piperacillin/Tazobactam Valuable Empiric Therapy For Febrile Neutropenia October 31, 2003
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
